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Abstract
Vitiligo is a psychologically devastating clinical conundrum which affects approximately 1% of the general
population. The exact cause of the illness is an enigma, but several hypotheses about its pathogenesis are
advanced.
The autoimmune hypothesis proposes an autoimmune attack against melanocytes. Although anti-melanocyte
autoantibodies have been demonstrated in vitiligo, recent research casts doubt on their pathogenic role and
instead supports the involvement of cell-mediated autoimmune response in the pathobiology of this disorder,
which is characterized by increase of suppressor T-cells and decrease of the helper/suppressor ratio in association
with the presence of type-1 cytokine secreting cytotoxic T cells in the vicinity of disappearing melanocytes.
The neural hypothesis proposes that increased release of norepinephrine, a melanocytotoxin, from the autonomic
nerve endings in the microenvironment of melanocytes injures these cells. Moreover, norepinephrine induces the
catecholamine degrading enzyme monoamine oxidase (MAO), which favors the formation of toxic levels of
hydrogen peroxide in the vicinity of melanocytes.
Another theory suggests that abnormal permeability of melanosome membrane, which normally prevents the
diffusion of toxic melanin precursors into the cytoplasm, may cause melanocyte damage.
Phenytoin, the widely-used anticonvulsant, has been employed both topically and systemically in the treatment of
some dermatological disorders. The drug has been shown to significantly suppress mitogen-induced activation of
lymphocytes and cytotoxic T lymphocyte activity and to polarize the immune response toward the type-2
pathway. It also significantly decreases suppressor T cells and increases the helper/suppressor ratio.
At high concentrations, the drug inhibits the release of norepinephrine and the activity of MAO. Moreover,
phenytoin is suggested to interact with membrane lipids, which may promote stabilization of the membranes.
The hydantoin moiety of phenytoin exerts a direct stimulatory action on melanocytes; facial hyperpigmentation
is a recognized side effect of orally administered phenytoin.
Altogether, the above evidence suggests that phenytoin could be therapeutically effective against vitiligo. As
phenytoin stimulates collagen production and inhibits its breakdown, its concomitant use with topical steroids
could prevent steroid-induced skin atrophy while potentiating the anti-vitiligo effect of these agents.
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recalcitrant skin disorder, affects approximately 1% of the
general population [1]. Theories concerning the cause of
vitiligo have focused on three different mechanisms: auto-
immune, neural, and autocytotoxic. The autoimmune
hypothesis proposes an autoimmune attack against
melanocytes. The autocytotoxic theory postulates that
cytotoxic precursors to melanin synthesis accumulate in
melanocytes, causing cell death. The neural hypothesis
proposes that the elevated levels of some neurotransmit-
ters and catecholamine degrading enzymes injure
melanocytes [2].
The important aspects of each theory pertinent to the
present paper are discussed below.
I) Evidence for involvement of cell-mediated 
immunity in the pathogenesis of vitiligo
Although melanocyte-specific autoantibodies have been
demonstrated in vitiligo, their pathogenic role remains
uncertain [1]. Though these autoantibodies have been
shown to be able to damage pigment cells both in vitro
and in vivo, more recently it has been reported that spe-
cific autoantibodies for tyrosinase are present at low fre-
quency in the sera of vitiligo patients, and that such
autoantibody titers may be found both in vitiligo-like
depigmentation (melanoma-associated depigmentation)
and in healthy controls [3]. The patchy distribution of
cutaneous depigmentation and the most frequent sym-
metrical distribution of lesions corroborate the concept
that autoimmune melanocyte damage is caused by clones
of lymphocytes with affinities for specific areas of skin [1].
In fact, high frequencies of circulating melanocyte-specific
CD8+ T cells expressing skin-homing capacity and exert-
ing anti-melanocyte cytotoxicity in vitro have been found
in vitiligo patients [3]. Moreover infiltrating activated T
lymphocytes have been observed at the periphery of vitil-
igo lesions and a recent immunopathologic study of
lesional skin of vitiligo patients noted a high frequency of
cutaneous lymphocyte antigen-positive activated cyto-
toxic T cells clustered in perilesional skin adjacent to the
disappearing melanocytes [4]. An increased level of solu-
ble interleukin (IL)-2 receptor, IL-6 and IL-8 has been
observed in vitiligo patients, which further suggests that T
cell activation may be a component in vitiligo pathogene-
sis [5].
Notably, perilesional T-cell clones exhibited a predomi-
nant type-1-like cytokine secretion profile, whereas the
degree of type-1 deviation in uninvolved skin-derived T-
cell clones correlated with the process of microscopically
observed melanocyte destruction in situ. Detailed analysis
of broad spectrum of cytokines produced by lesional- and
nonlesional-derived CD4+ and CD8+ T-cell clones con-
firmed deviation toward type-1-like in both CD4 and
CD8 compartments, which mirrored depigmentation
process observed locally in the skin [4]. The facts that vitil-
igo is found more frequently in patients with metastatic
melanoma and is associated with an improved prognosis,
and that vitiligo-like depigmentation has been observed
following immunotherapy of melanoma, further support
a crucial role for cell-mediated immunity in the pathogen-
esis of the disorder [5].
It deserves noting that the peripheral blood of patients
with vitiligo shows a significant decrease in helper cells
and helper/suppressor ratios in comparison with control
subjects [6].
An association between CD8+ T lymphocyte reactivity to
the melanocyte antigen gp100, and to a lesser extent
Melan A/MART-1, and vitiligo has been demonstrated.
Furthermore, the disease activity appears correlated with
reactivity to gp100 [5].
II) Involvement of increased norepinephrine 
(NE) and monoamine oxidase (MAO) levels in 
the pathogenesis of vitiligo
It has recently been demonstrated that axon terminals and
epidermal melanocytes make contact via chemical syn-
apses in human skin [2,7].
An increased release of catecholamine from the auto-
nomic nerve endings in the microenvironment of
melanocytes in the vitiliginous areas has been reported.
NE is known for having direct and indirect toxic effects on
melanocytes [2,7].
Direct actions include interacting with cellular sulfhydryl
groups, enzyme inhibition, impairing mitochondrial cal-
cium uptake, and forming some cytotoxic products such
as free radicals. Indirect actions include activating α-recep-
tors of skin arterioles causing a severe vasoconstriction,
thereby producing toxic oxygen radicals due to hypoxia
[2,7]. Moreover, elevated level of NE secreted by keratino-
cytes or by nerve endings induces the catecholamine
degrading enzyme monoamine oxidase (MAO). Increased
MAO activity favors the formation of toxic levels of hydro-
gen peroxide, which is not buffered due to the low cata-
lase activity in vitiliginous skin [2,7].
III) Abnormal permeability of melanosome 
membrane as a potential pathogenic factor in 
vitiligo
Tyrosine, a derivative of phenol, is oxidized into melanin
via a complex series of oxidative reactions, often accompa-
nied by electronic rearrangements within molecules.
Some of these products are unstable and capable of form-
ing radicals that react with other molecules in the cell. It is
thought that melanin synthesis is confined within thePage 2 of 4
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diffusing into the cell where they might disrupt essential
metabolic pathways, leading to the destruction of the pig-
ment cell.
Defects either inherited or acquired in the membranes of
melanosomes resulting in the demise of melanocytes are
supposed to cause vitiligo [8].
IV) Phenytoin exerts an inhibitory effect on the 
pathomechanism behind vitiligo but a direct 
stimulatory action on melanocytes
Phenytoin (dilantin), a diphenyl-substituted hydantoin,
is a widely prescribed anticonvulsant agent which has
been used in cutaneous medicine in the treatment of
ulcers, inflammatory conditions, and epidermolysis bul-
losa [9]. Interestingly, this agent possesses a myriad of
effects which make it potentially effective against vitiligo:
Phenytoin is documented to significantly suppress
mitogen-induced activation of lymphocytes [10,11], cyto-
toxic T lymphocyte activity [11-14] and cell-mediated
immunity [15], polarizing the immune response toward a
type-2-like cytokine secretion profile [14]. Additionally, it
significantly decreases suppressor T-cells and increases the
helper/suppressor ratio [16,17].
Phenytoin inhibits the production of superoxide anion by
immune cells [18] and significantly improves rheumatoid
arthritis, a cell-mediated autoimmune disorder [19].
Interestingly, some in vitro studies have shown that this
drug, at high concentrations, which may also be reached
by the topical application, inhibits the release of NE and
inhibits the activity of MAO [20]. it is also speculated that
the agent may interact with membrane lipids (and con-
ceivably with melanosome membrane lipids as well),
which could promote the stabilization of the membranes
[20].
Melasma (chloasma), the facial hypermelanosis produced
by hyperfunctional melanocytes, is a recognized side
effect of orally administered phenytoin [9,21]. It has been
suggested that the hydantoin moiety exerts a direct action
on the melanocytes; it has been shown to expand melan-
ophores in amphibian larvae [21].
In conclusion, given its inhibitory effect on cell-mediated
immunity, NE release, and MAO activity and also in view
of its potential ability to stabilize melanosome membrane
and to stimulate melanocytes, phenytoin may prove to be
effective against vitiligo. Importantly, as phenytoin facili-
tates collagen deposition and inhibits collagenase activity
[9], its concomitant topical use with steroids may prevent
steroid-induced skin atrophy while potentiating the anti-
vitiligo effect of these agents. The latter effect could occur
through phenytoin's ability to directly stimulate melano-
cyte proliferation, which is lacked by steroids. Moreover,
the immunomodulatory effect of this agent, which may
be employed topically in relatively high concentrations
without producing the untoward systemic effects, may
permit the reduction of the concentration of the topical
steroids (steroid-sparing effect) and thus their frequently-
occurring dermatologic side effects. As the closing com-
ment, topically-administered phenytoin was shown to
exert significant immunomodulatory activity and be effec-
tive against lichen planus [22], which could reasonably be
the case in vitiligo as well.
V) Testing this hypothesis
This hypothesis can be tested using animal models of vitil-
igo such as the Smyth chicken. The Smyth chicken
expresses the major features of human vitiligo – the
delayed development of cutaneous amelanosis, most
commonly appearing during adolescence or at young
adulthood, and variable in occurrence, location and
extent [23]. The etiology of vitiligo in the Smyth chicken
appears to include an inherent defect in the melanocytes
and an associated autoimmune response [24]. Though the
Smyth chicken does not incorporate all the genetic and
environmental factors which may do or cause vitiligo in
humans, it is an excellent model for the study of human
vitiligo in that it parallels the human condition in varia-
bility, complexity, mode of expression, and polyfactorial
etiology. As complement to animal studies, this hypothe-
sis could be tested most rigorously in patients suffering
from bilateral lesions by applying a topical preparation of
phenytoin to the lesion(s) of one side of the body and a
topical placebo to the contralateral lesion(s), then com-
paring the results (double-blind, placebo-controlled,
bilateral paired comparison method).
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